Literature DB >> 9918480

Prevalence of lysosomal storage disorders.

P J Meikle1, J J Hopwood, A E Clague, W F Carey.   

Abstract

CONTEXT: Lysosomal storage disorders represent a group of at least 41 genetically distinct, biochemically related, inherited diseases. Individually, these disorders are considered rare, although high prevalence values have been reported in some populations. These disorders are devastating for individuals and their families and result in considerable use of resources from health care systems; however, the magnitude of the problem is not well defined. To date, no comprehensive study has been performed on the prevalence of these disorders as a group.
OBJECTIVE: To determine the prevalence of lysosomal storage disorders individually and as a group in the Australian population.
DESIGN: Retrospective case studies.
SETTING: Australia, from January 1, 1980, through December 31, 1996. MAIN OUTCOME MEASURE: Enzymatic diagnosis of a lysosomal storage disorder.
RESULTS: Twenty-seven different lysosomal storage disorders were diagnosed in 545 individuals. The prevalence ranged from 1 per 57000 live births for Gaucher disease to 1 per 4.2 million live births for sialidosis. Eighteen of 27 disorders had more than 10 diagnosed cases. As a group of disorders, the combined prevalence was 1 per 7700 live births. There was no significant increase in the rate of either clinical diagnoses or prenatal diagnoses of lysosomal storage disorders during the study period.
CONCLUSIONS: Individually, lysosomal storage disorders are rare genetic diseases. However, as a group, they are relatively common and represent an important health problem in Australia.

Entities:  

Mesh:

Year:  1999        PMID: 9918480     DOI: 10.1001/jama.281.3.249

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  584 in total

Review 1.  Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.

Authors:  F M Platt; M Jeyakumar; U Andersson; D A Priestman; R A Dwek; T D Butters; T M Cox; R H Lachmann; C Hollak; J M Aerts; S Van Weely; M Hrebícek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

2.  Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention.

Authors:  A H Miners; A Holmes; L Sherr; C Jenkinson; K D MacDermot
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

Review 3.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

4.  Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Robin L Bennett; Kimberly A Hart; Erin O'Rourke; John A Barranger; Jack Johnson; Kay D MacDermot; Gregory M Pastores; Robert D Steiner; Ravi Thadhani
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

5.  Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry.

Authors:  Yung-Hsiu Lu; Po-Hsun Huang; Li-Yun Wang; Ting-Rong Hsu; Hsing-Yuan Li; Pi-Chang Lee; Yu-Ping Hsieh; Sheng-Che Hung; Yu-Chen Wang; Sheng-Kai Chang; Ya-Ting Lee; Ping-Hsun Ho; Hui-Chen Ho; Dau-Ming Niu
Journal:  J Hum Genet       Date:  2017-11-15       Impact factor: 3.172

6.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

7.  Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA.

Authors:  Robin K Rumsey; Kyle Rudser; Kathleen Delaney; Michael Potegal; Chester B Whitley; Elsa Shapiro
Journal:  J Pediatr       Date:  2014-02-25       Impact factor: 4.406

8.  Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Authors:  B Hoffmann; A Garcia de Lorenzo; A Mehta; M Beck; U Widmer; R Ricci
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

9.  SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases.

Authors:  L Ou; M J Przybilla; C B Whitley
Journal:  Clin Genet       Date:  2018-03-05       Impact factor: 4.438

10.  A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.

Authors:  N M Ellinwood; P Wang; T Skeen; N J H Sharp; M Cesta; S Decker; N J Edwards; I Bublot; J N Thompson; W Bush; E Hardam; M E Haskins; U Giger
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.